Ultragenyx Pharmaceutical Inc. buy marge
Start price
19.04.17
/
50%
€58.68
Target price
20.07.17
€63.14
Performance (%)
7.76%
End price
20.07.17
€63.23
Summary
This prediction ended on 20.07.17 with a price of €63.23. With a performance of 7.76%, the BUY prediction by marge for Ultragenyx Pharmaceutical Inc. closed with a slight gain. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 15.569% | 15.569% | -34.354% | -46.978% |
| iShares Core DAX® | 4.852% | -2.747% | 13.097% | 46.787% |
| iShares Nasdaq 100 | 3.999% | -3.330% | 31.335% | 76.979% |
| iShares Nikkei 225® | 4.221% | -2.912% | 44.472% | 49.876% |
| iShares S&P 500 | 3.324% | -2.954% | 24.360% | 57.274% |
Comments by marge for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical m. Tradingchance on positive results for hypophosphatemia drug test
Ultragenyx Pharmaceutical (NASDAQ:RARE) +19.8% AH on news that its burosumab drug to treat x-linked hypophosphatemia, a genetic kidney disorder, met its primary endpoint in a phase 3 study.
RARE says patients treated with the drug showed a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels vs. 8% on placebo.